About this medicine

Methadone can support stable treatment of opioid dependence. Treatment includes continuing review and psychosocial care, not simply replacement of one drug with an unsupervised supply of another.

Maintenance can be long-term; it is not a treatment failure when continuing prescribed medicine helps someone remain stable. Detoxification is a different agreed goal. A GP or local drug-treatment service can explain access, with arrangements differing across the four UK nations.

What is this medicine used for?

The selected 1 mg/mL solution is authorised for opioid-dependence treatment. Other pain formulations or concentrated liquids need their own prescribing information; identical ingredient names do not make directions interchangeable.

Methadose oral concentrate is another verified dependence-treatment product. Methadone is also used in specialist pain care in other presentations, but analgesic and dependence regimens are not interchangeable. A person on maintenance treatment still needs assessment and a separate plan for acute pain.

Which warning signs need help?

Slow or shallow breathing, inability to wake or suspected overdose requires emergency help immediately, even if the person initially seems well. Secure storage protects children and other people who may have little or no opioid tolerance.

Have an overdose plan and ask about take-home naloxone. If someone is unconscious or struggling to breathe, call emergency services and use available naloxone according to the product instructions or call handler. Methadone may outlast naloxone, so stay with the person and obtain emergency care even after improvement. An extra dose also needs prompt medical advice before symptoms develop.

How do I take it safely?

The liquid concentration is 1 mg/mL, not a recommended dose. The addiction service sets an individual induction and maintenance regimen. Use the supplied measuring device and pharmacy label; do not use another product's volume instructions.

The selected product describes a usual adult daily range of 60–120 mg, reached through individual supervised titration rather than as a starting dose. Tolerance, sedatives and delayed accumulation can make an apparently familiar dose unsafe.

Induction sources must be read in context. The current Martindale SmPC describes 10–20 mg initially and larger daily increments than the Orange Book's cautious usual titration. The Orange Book describes an initial range of 10–30 mg with reassessment, generally smaller increments and limits on weekly escalation. These are not competing home schedules: the treating service must reconcile the exact product with specialist guidance and observed toxicity.

Methadose 10 mg/mL is an oral concentrate intended for dilution by the pharmacy or prescriber. Its leaflet's regimen is not the same as the Martindale solution's reference range. Always check the final dispensed concentration; confusing milligrams with millilitres or using the volume from a previous bottle can cause a serious overdose.

What side effects should I know about?

Dizziness, dry mouth and urinary difficulty can occur as well as bowel symptoms. Drowsiness may be a warning of excess opioid effect, particularly after a change or with another sedative.

Who needs extra care with this medicine?

The checked product excludes respiratory depression, acute alcohol intoxication, severe liver impairment and certain acute illnesses. Heart-rhythm risk and electrolyte problems need assessment; repeated doses require particular caution in frailty.

Can it affect my other medicines?

Alcohol, benzodiazepines, gabapentin and pregabalin can compound breathing risk. QT-prolonging and serotonergic drugs, enzyme-altering medicines and MAO inhibitors need a prescriber or pharmacist's review.

What check-ups will I need?

Review sedation, withdrawal control, substance use and interactions; assess ECG and electrolyte needs from individual risk. England's updated guidance individualises supervision instead of automatically imposing the old fixed duration.

The SmPC recommends an ECG before treatment and at stabilisation when QT risk factors exist. Without recognised factors, it recommends an ECG before titration above 100 mg/day and again seven days later. These checks supplement, not replace, clinical observation.

What about pregnancy, breastfeeding and age?

The Orange Book supports stable substitution treatment during pregnancy and coordinated maternity/addiction care. Increased clearance later in pregnancy can require specialist dose review. The Martindale SmPC requires benefit–risk assessment and lists use during labour as a contraindication. These differences need an agreed specialist birth plan; do not independently stop maintenance treatment or interpret it as labour analgesia.

The current Martindale SmPC permits a specialist breastfeeding decision with infant monitoring, while its patient leaflet has more restrictive wording. NHS SPS supports methadone with caution for healthy full-term infants. Watch for marked sleepiness, breathing difficulty and inadequate weight gain; premature or unwell infants need specialist advice. Neither abrupt cessation of treatment nor abrupt weaning should be inferred from a short medicine summary.

The named oral products restrict paediatric use; adult reference doses are not a children's treatment protocol. Frailty, illness and impaired organ function can make repeated dosing less predictable.

What if I miss a dose or want to stop?

Do not double a missed dose. Contact the treatment service if doses have been missed, because reduced tolerance can make restarting the previous amount unsafe. Planned stopping usually involves gradual reduction.

Tell the pharmacy and prescriber about a missed supervised dose; the pharmacy may need fresh instructions before supplying it. Hospital and community teams should verify the last dose and arrange continuity, not assume that collecting a prescription proves the full amount was taken.

How does it work?

Methadone activates opioid receptors, receiving sites used by medicines and drugs such as morphine and heroin. This can suppress craving and withdrawal, the physical and emotional symptoms that follow a reduction in opioid effects after the body has adapted to them. Methadone can also slow breathing, so beneficial and harmful effects can occur together.

How Brain Cells Communicate

Opioid receptors help regulate communication between nerve cells in systems involved in pain, reward and breathing. The mu receptor is one important type. An agonist is a substance that attaches to a receptor and activates it, changing the signal passed through the cell. With repeated opioid exposure, the body adapts, which can lead to tolerance and physical dependence.

What is known: Tolerance means reduced sensitivity to some effects; dependence means withdrawal can follow a substantial reduction.

What remains uncertain: Adaptation to one opioid effect does not ensure equal protection against every harmful effect.

Opioid agonist: Mu-opioid receptor

A messenger acts at a solid membrane receptor; protein coupling inside the cell illustrates a signaling response, rather than passage through an ion pore. Opioid agonist: A messenger can change signaling through its receptor. Mu-opioid receptor: This receptor symbol identifies a function, not a molecular structure. Cell response: The arrow represents a signaling response, not movement through a pore.
  1. Opioid agonist

    A messenger can change signaling through its receptor.

  2. Mu-opioid receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Cell response

    The arrow represents a signaling response, not movement through a pore.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Opioid agonist can activate mu-opioid receptor and change signaling in the cell.

Tolerance means reduced sensitivity to some effects; dependence means withdrawal can follow a substantial reduction. Simplified illustration of the process; individual responses vary.
About this illustration

Biological process; Molecular action; Clinical effect. Adaptation to one opioid effect does not ensure equal protection against every harmful effect.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How the Medication Changes Signaling

Methadone is a full agonist at mu receptors, meaning it can produce the full activating response of this type of opioid drug. Continued activation can prevent the abrupt loss of opioid signaling that contributes to withdrawal. Laboratory findings also suggest an effect at NMDA receptors, receiving sites involved in signaling by glutamate, an activating brain messenger. How much this additional action contributes to methadone’s clinical effects remains uncertain.

What is known: Mu-receptor activation is the main established explanation for methadone’s opioid effects.

What remains uncertain: The possible NMDA action does not account for a known proportion of its benefit.

Methadone: Mu-opioid receptor

A terracotta medicine symbol activates a membrane receptor; intracellular protein coupling represents a response without an ion pore. Methadone: The oval identifies the medicine acting at the Mu-opioid receptor. It is a concept symbol, not a molecular shape or binding pose. Mu-opioid receptor: This receptor symbol identifies a function, not a molecular structure. Methadone: activation: The arrow represents a signaling response, not movement through a pore.
  1. Methadone

    The oval identifies the medicine acting at the Mu-opioid receptor. It is a concept symbol, not a molecular shape or binding pose.

  2. Mu-opioid receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Methadone: activation

    The arrow represents a signaling response, not movement through a pore.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Methadone is a full mu-opioid receptor agonist. This target action can contribute to both therapeutic and harmful opioid effects.

Mu-receptor activation is the main established explanation for methadone’s opioid effects. Simplified illustration of the process; individual responses vary.
About this illustration

Medicine; Target or pathway; Intended effects. The possible NMDA action does not account for a known proportion of its benefit.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

A Closer Look at the Molecular Level

Methadone is processed by liver enzymes, proteins that help break medicines down, and the speed varies widely between people. It can also remain in body tissues and return gradually to the blood. Repeated doses may therefore build on medicine still present from earlier doses, increasing effects over several days. Other medicines can alter this processing, changing exposure even when the methadone dose itself has not changed.

What is known: Slow, variable removal and tissue storage both influence continuing exposure.

What remains uncertain: An initially tolerated dose does not establish that later accumulation will be safe.

How the process works

  1. Dose and delivery
  2. Drug exposure
  3. Benefit and harm
Slow, variable removal and tissue storage both influence continuing exposure. Simplified illustration of the process; individual responses vary.
About this illustration

Dose and delivery; Drug exposure; Benefit and harm. An initially tolerated dose does not establish that later accumulation will be safe.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How does it affect my body?

Constipation, nausea and sweating can occur. Treatment should support everyday functioning rather than intoxication. Persistent symptoms deserve review instead of adding medicines without checking interactions.

Longer-term opioid effects can include altered sex-hormone function. Persistent loss of libido, menstrual changes or unusual fatigue deserve assessment rather than being attributed automatically to mental illness or recovery.

How does my body process it?

Methadone accumulates in tissues and its half-life varies markedly. An apparently tolerated early dose can become dangerous after repeated dosing; initiation and escalation require close clinical assessment.

How do treatment options differ?

Methadone and buprenorphine differ in receptor action and initiation risks. Neither is universally preferable. England guidance supports offering an informed choice when appropriate, within a treatment and support programme.

Buprenorphine's partial-agonist profile changes overdose and induction risks; methadone may suit people who do not stabilise with it. Treatment choice should consider previous response, cardiac or respiratory disease, other sedatives, and practical access to dispensing, not a blanket ranking of one medicine as best.

A closer look at the science

Its full mu-opioid agonism has no protective ceiling against respiratory depression. Activating the same receptor over a prolonged period can suppress withdrawal while also slowing breathing. Molecular action does not determine a safe starting dose: tolerance, accumulation and interactions matter.

Methadone is a synthetic opioid supplied as a hydrochloride salt and a racemic mixture.

Chemical formula: C21H27NO · HCl

The verified image shows neutral methadone connectivity, C21H27NO, without resolving the product’s enantiomer mixture. Chloride is omitted; the drawing does not determine tolerance or a safe dose.

Neutral methadone connectivity without a specified enantiomer; hydrochloride omitted.
NCBI PubChem CID 4095. Lines are bonds; unlabeled corners are carbon and many hydrogen atoms are omitted. This neutral-parent drawing is connectivity, not a binding pose.

The drawing shows the neutral parent. The product salt formula is separately identified; neither determines release rate or dose.

How was this medicine developed?

England's 2024 DHSC update supplements earlier guidance; its changes must not be described as automatically replacing local pathways across all four UK nations.

Sources and References

  1. Methadone 1 mg/mL oral solution sugar-free: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  2. Methadone 1 mg/mL oral solution sugar-free: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  3. Oral methadone and buprenorphine: recommendations

    Scope: England.

  4. Treating opioid dependence during breastfeeding

    Scope: UK medicines advice; healthy full-term infants.

  5. About methadone

    Scope: UK medicine information; service links chiefly England.

  6. Methadose 10 mg/1 mL oral concentrate: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  7. Drug misuse and dependence: UK guidelines on clinical management (2017)

    Scope: United Kingdom clinical guidance; local service arrangements vary.

  8. Methadose 10 mg/1 mL oral concentrate: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  9. How and when to take methadone

    Scope: UK patient information; service links principally England.

  10. Supplying take home naloxone without a prescription

    Scope: United Kingdom; local supply arrangements vary.

  11. Methadone: current prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.2 Pharmacodynamics; 12.3 Pharmacokinetics; 9.3 Dependence; 5.1 Life-Threatening Respiratory Depression..

  12. Methadone: verified neutral parent, PubChem CID 4095

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  13. All Opioid Pain Medicines: Drug Safety Communication - FDA Updates Prescribing Information to Provide Additional Guidance for Safe Use | FDA
  14. New Safety Measures Announced for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepines | FDA

Shared scientific background. US product pharmacology and international chemical references do not establish UK licences, doses, formulations or NHS recommendations.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top